Digestive System Diseases

646 trials 307 recruiting

Filter these 646 trials by phase, country and sponsor.

Open in Search →

Intraperitoneal treatment with fosfomycin, metronidazole and recombinant human granulocyte-macrophage colony-stimulating factor in patients … Not authorised

2024-520317-49-00 peritonitis 3
Studio clinico pilota: utilizzo di una nuova formulazione di Budesonide Viscosa in bambini con Esofagite Eosinofila - BUDEOE Not authorised

2024-512395-36-00 Eosinophilic Esophagitis 4
A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Pati… Not authorised

2022-502043-35-00 Advanced Biliary Tract Cancers 5
ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Not authorised

2022-500535-36-00 Moderately to severely active ulcerative colitis 5
ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Not authorised

2022-500536-11-00 Moderately to severely active ulcerative colitis 5
ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised

2022-500537-84-00 Moderately to severely active ulcerative colitis 5
An open label safety and efficacy study of allogenic adipose tissue-derived mesenchymal stromal cells on autism and gastrointestinal symptom… Not authorised

2025-523699-21-00 Gastrointestinal symptoms 3
A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCER Not authorised

2023-508058-24-00 LOCALLY ADVANCED OR METASTATIC LOW TUMOR VOLUME COLOREC 1
Safety, tolerability, and efficacy of mFOLFIRINOX ±BNT321 as adjuvant therapy following curative resection in patients with pancreatic adeno… Not authorised

2023-506014-47-00 Resected (R0 or R1) pancreatic ductal adenocarcinoma 9
FusionVAC22_01: DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocel… Not authorised

2022-502869-17-00 tumor entities carrying the oncogenic driver fusion DNA 1
An European multinational study of a personalized approach of human albumin administration in patients with cirrhosis of the liver and compl… Not authorised

2022-501006-34-00 Liver cirrhosis 5
A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown

2025-523766-25-00 Ulcerative colitis 5
Vi-Siblin for LARS: A randomized, controlled trial. Pending

2024-514541-11-00 Low anterior resection syndrome after low anterior rese 4
A Randomized, Non-inferiority Trial Comparing 7-Day Versus 4-Week Esomeprazole Treatment in Patients with Unexplained Dyspepsia Pending

2025-524044-35-00 Dyspepsia 6
Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with adv… Pending

2025-524048-36-00 Advanced HER2-negative and PD-L1 positive gastroesophag 5
Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE) Pending

2024-518138-10-00 Patients with DMMR and/or MSI metastatic colorectal can 4
Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Duct… Pending

2024-518139-12-00 locally advanced or metastatic Pancreatic ductal adenoc 4
EFFICACY OF USUAL MANAGEMENT BY LOCAL ANESTHETIC INFILTRATION IN THE TREATMENT OF CHRONIC IDIOPATHIC ANO-PERINEAL PAIN: A RANDOMIZED DOUBLE-… Pending

2024-518148-19-00 chronic idiopathic ano-perineal pain 5
A PHASE 1 STUDY WITH SINGLE ASCENDING DOSE, MULTIPLE ASCENDING DOSE AND FOOD EFFECT OF LMT503 IN HEALTHY SUBJECTS. Pending

2024-519180-17-00 Healthy volonteers 1
Intraperitoneal treatment with fosfomycin, metronidazole and recombinant human granulocyte-macrophage colony-stimulating factor in patients … Pending

2024-520317-49-02 peritonitis 3
PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients … Pending

2024-519753-11-00 Resectable borderline pancreatic adenocarcinoma 4
A randomized, balanced, two-treatment, two-sequence, single oral dose, two stage crossover adaptative bioequivalence study of Rifaximin 200 … Pending

2025-525078-12-00 healthy subjects 2
Optimal Duration of Antibiotic Therapy in Drained Pyogenic Liver Abscess: 3 weeks versus 6 weeks, a non-inferiority trial Pending

2025-520940-14-00 Pyogenic liver abscess 6
J6Z-MC-IIBD - A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn’s Disease J6Z-MC-CD01 - A Stud… Pending

2025-524112-11-00 J6Z-MC-IIBD - Colitis, Ulcerative Crohn Disease J6Z-M 4